RAC 2.20% $1.78 race oncology ltd

Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-133

  1. 6,972 Posts.
    lightbulb Created with Sketch. 866
    so the reformulation and start from phase 1 again is to target a wider market….. So the original formula wasn’t up to scratch to take to market? Is that your angle?

    Plain and simples
    Last edited by Bluegumnuts: 09/07/24
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.